Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

2.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.

3.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
4.

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA.

Pathology. 2016 Apr;48(3):261-6. doi: 10.1016/j.pathol.2016.01.001. Epub 2016 Mar 9.

PMID:
27020503
5.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

6.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
7.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P.

Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.

8.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.

Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.

PMID:
25452114
9.

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients.

Mactier S, Kaufman KL, Wang P, Crossett B, Pupo GM, Kohnke PL, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1106-16. doi: 10.1111/pcmr.12290. Epub 2014 Aug 14.

10.

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P.

J Invest Dermatol. 2014 Nov;134(11):2795-2805. doi: 10.1038/jid.2014.243. Epub 2014 Jun 6.

11.

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H.

Mol Oncol. 2014 May;8(3):544-54. doi: 10.1016/j.molonc.2014.01.003. Epub 2014 Jan 15.

12.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

13.

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV.

Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24.

14.

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW, Mann GJ, Thompson JF, Scolyer RA, Hayward NK.

Pigment Cell Melanoma Res. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23.

PMID:
23890154
15.

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, Rizos H.

Mol Cancer Ther. 2013 Jul;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3.

16.

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.

Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford RF, Zhang XD, Rizos H.

Oncogene. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4.

PMID:
23455323
17.

p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.

Fung C, Pupo GM, Scolyer RA, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2013 Mar;26(2):236-46. doi: 10.1111/pcmr.12062. Epub 2013 Jan 24.

PMID:
23279822
18.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM.

J Invest Dermatol. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29.

19.

A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration.

Zhou L, Pupo GM, Gupta P, Liu B, Tran SL, Rahme R, Wang B, Rua R, Rizos H, Carroll A, Cairns MJ, Saksena NK.

BMC Genomics. 2012 Nov 28;13:677. doi: 10.1186/1471-2164-13-677.

20.

Cellular blue naevus involving the urinary bladder.

Kim J, McCarthy SW, Thompson JF, Pupo GM, Vonthethoff L, Nash P, Mann GJ, Scolyer RA.

Pathology. 2012 Dec;44(7):664-8. doi: 10.1097/PAT.0b013e328359e142. No abstract available.

PMID:
23172087
21.

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA.

J Invest Dermatol. 2013 Feb;133(2):509-17. doi: 10.1038/jid.2012.283. Epub 2012 Aug 30.

22.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

23.

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H.

J Invest Dermatol. 2012 Jul;132(7):1850-9. doi: 10.1038/jid.2012.63. Epub 2012 Mar 22. Erratum in: J Invest Dermatol. 2013 Oct;133(10):2493.

24.

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.

Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, Lanagan C, Carter CD, O'Connor L, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK.

Mol Cancer Ther. 2012 Apr;11(4):888-97. doi: 10.1158/1535-7163.MCT-11-0676. Epub 2012 Mar 1.

25.

Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.

Dutton-Regester K, Aoude LG, Nancarrow DJ, Stark MS, O'Connor L, Lanagan C, Pupo GM, Tembe V, Carter CD, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK.

Genes Chromosomes Cancer. 2012 May;51(5):452-61. doi: 10.1002/gcc.21932. Epub 2012 Jan 17.

PMID:
22250051
26.

Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.

Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury EL, Bilous AM, Byth K; KConFab Investigators, Mann GJ.

Genes Chromosomes Cancer. 2010 Dec;49(12):1082-94. doi: 10.1002/gcc.20816.

PMID:
20815029
27.

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.

Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021.

28.

Is MSH2 a breast cancer susceptibility gene?

Wong EM, Tesoriero AA, Pupo GM; kConFab; ABCFS, McCredie MR, Giles GG, Hopper JL, Mann GJ, Goldgar DE, Southey MC.

Fam Cancer. 2008;7(2):151-5. Epub 2007 Oct 6.

PMID:
17922223
29.

BCoR-L1 variation and breast cancer.

Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Khanna KK, Chenevix-Trench G, Spurdle AB.

Breast Cancer Res. 2007;9(4):R54. Erratum in: Breast Cancer Res. 2008;10(5):406.

30.

Mutation analysis of five candidate genes in familial breast cancer.

Marsh A, Healey S, Lewis A, Spurdle AB, Kedda MA, Khanna KK; kConFab, Mann GJ, Pupo GM, Lakhani SR, Chenevix-Trench G.

Breast Cancer Res Treat. 2007 Nov;105(3):377-89. Epub 2006 Dec 23.

PMID:
17187232
31.

Variation in the RAD51 gene and familial breast cancer.

Lose F, Lovelock P, Chenevix-Trench G, Mann GJ, Pupo GM, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.

Breast Cancer Res. 2006;8(3):R26. Epub 2006 Jun 8.

32.

A genome wide linkage search for breast cancer susceptibility genes.

Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, Chenevix-Trench G; kConFab Investigators, Szabo C, Southey M, Renard H, Odefrey F, Lynch H, Stoppa-Lyonnet D, Couch F, Hopper JL, Giles GG, McCredie MR, Buys S, Andrulis I, Senie R; BCFS, BRCAX Collaborators Group, Goldgar DE, Oldenburg R, Kroeze-Jansema K, Kraan J, Meijers-Heijboer H, Klijn JG, van Asperen C, van Leeuwen I, Vasen HF, Cornelisse CJ, Devilee P, Baskcomb L, Seal S, Barfoot R, Mangion J, Hall A, Edkins S, Rapley E, Wooster R, Chang-Claude J, Eccles D, Evans DG, Futreal P, Nathanson KL, Weber BL; Breast Cancer Susceptibility Collaboration (UK), Rahman N, Stratton MR.

Genes Chromosomes Cancer. 2006 Jul;45(7):646-55.

33.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res. 2006;8(1):R12. Epub 2006 Feb 13.

34.

Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.

Breast Cancer Res. 2005;7(6):R1005-16. Epub 2005 Oct 21.

35.

Dominant negative ATM mutations in breast cancer families.

Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dörk T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK.

J Natl Cancer Inst. 2002 Feb 6;94(3):205-15. Erratum in: J Natl Cancer Inst 2002 Jun 19;94(12):952.

PMID:
11830610
36.

The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.

Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, Mann GJ, Hopper JL, Sambrook JF, Chenevix-Trench G; Australian Breast Cancer Family Study; Kathleen Cuningham Foundation for Research into Familial Breast Cancer.

Breast Cancer Res. 2001;3(5):346-9. Epub 2001 Jul 17.

37.

Population genetics of Escherichia coli in a natural population of native Australian rats.

Pupo GM, Lan R, Reeves PR, Baverstock PR.

Environ Microbiol. 2000 Dec;2(6):594-610.

PMID:
11214793
38.
40.

Supplemental Content

Support Center